Analyst Price Target is $67.00
▲ +49.64% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is $67.00, with a high forecast of $79.00 and a low forecast of $50.00. The average price target represents a 49.64% upside from the last price of $44.78.
Current Consensus is
Moderate Buy
The current consensus among 9 polled investment analysts is to moderate buy stock in Enovis. This rating has held steady since May 2024, when it changed from a Buy consensus rating.
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Read More